200
Participants
Start Date
December 10, 2019
Primary Completion Date
May 1, 2020
Study Completion Date
May 1, 2020
Intervention in the UroCCR sites
"1. Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent)~2. DNA extraction:~ * For the patients of Bordeaux University Hospital, 2 aliquots will be constituted:~ * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA,~ * 1 aliquot for the UroCCR biobank.~ * For patients from other UroCCR centers, only 1 aliquot will be constituted:~ * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA.~3. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux."
Intervention in the CRB of Bordeaux University Hospital
"1. Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank.~2. Overall packing of GWAS samples for shipment to the NCI.~3. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study."
Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital
Transfer of the data associated with the samples to the NCI.
Subsequent intervention at the NCI (for information)
"1. Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network.~2. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples."
Centre Hospitalier Universitaire de Bordeaux, Talence
National Cancer Institute (NCI)
NIH
University Hospital, Bordeaux
OTHER